Targeting a gene linked to autism using innovative therapies
miRNA site-blocking ASOs as MeCP2 targeted therapeutics
This study is exploring a new way to help people with autism-related disorders, like Rett syndrome, by using a special treatment that boosts a key gene in the brain, aiming for safer and more effective results.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Loyola University Chicago NIH-funded |
| Lab location | 1 site (Maywood, United States) |
| Project ID | NIH-10820414 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treat autism-related disorders by targeting the Methyl-CpG Binding Protein 2 (MeCP2) gene, which is crucial for brain development. The study aims to enhance the expression of MeCP2 in a controlled manner using antisense oligonucleotides (ASOs) that block specific microRNAs, thereby fine-tuning protein levels to avoid adverse effects. By preventing the binding of repressive microRNAs to the gene's regulatory region, the researchers hope to achieve a therapeutic effect without the risks associated with traditional gene therapy methods. This approach could lead to safer and more effective treatments for conditions like Rett syndrome and other autism spectrum disorders.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with autism spectrum disorders, particularly those with Rett syndrome.
Not a fit: Patients with autism who do not have mutations in the MeCP2 gene or those with unrelated neurodevelopmental disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer therapeutic option for patients with autism-related disorders by precisely regulating gene expression.
How similar studies have performed: While the approach of using ASOs to modulate gene expression is gaining traction, this specific application targeting MeCP2 is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
Maywood, United States
- Loyola University Chicago — Maywood, United States (Active)
Researchers
- Principal investigator: Gogliotti, Rocco George — Loyola University Chicago
- Study coordinator: Gogliotti, Rocco George
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.